5T4 antibody drug conjugate and application thereof

By designing anti-5T4 antibody drug conjugates with specific sequences, the safety and effectiveness issues in the prior art were solved, and the significant inhibitory effect on a variety of tumors was achieved, and a new and safe antibody drug conjugate solution targeting 5T4 was provided.

CN120361243APending Publication Date: 2025-07-25LEPU BIOPHARMA CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202510733151.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-08-18
Filing Date
2024-08-16
Publication Date
2025-07-25

AI Technical Summary

Technical Problem

The existing 5T4-targeted antibody drug conjugates have safety and effectiveness problems in clinical research, especially dose-limiting toxicity and no objective remissions are observed. It is necessary to develop new, safe and more effective antibody drug conjugates that target 5T4.

Method used

A new anti-5T4 antibody drug conjugate is designed, with a specific antibody variable region sequence and a linker connected to the cytotoxin through covalent bonds to form an antibody drug conjugate, with a drug antibody ratio (DAR) of 1-10, the linker is selected from MC-AAN, MCC-AAQ, MC-vc-PAB, etc., and the cytotoxin is selected from topoisomerase inhibitors such as MMAE, MMAF, etc., and is coupled to the antibody by covalent bond.

Benefits of technology

It exhibits strong cell killing effects in a variety of tumor cells and significantly inhibits tumor cell growth in tumor models, with good biological activity and safety.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005432522380000021
    Figure BDA0005432522380000021
  • Figure BDA0005432522380000031
    Figure BDA0005432522380000031
  • Figure BDA0005432522380000032
    Figure BDA0005432522380000032
Patent Text Reader

Abstract

Relates to a 5T4 antibody drug conjugate and application thereof, and particularly provides the antibody drug conjugate, or pharmaceutically acceptable salt, solvate or solvate of the salt, the antibody drug conjugate has a structure as shown in a formula I, and Ab is an anti-5T4 antibody. The antibody drug conjugate has good tumor cell growth inhibition activity in vivo and in vitro, and has a good application prospect. Ab-(L-D) p formula I
Need to check novelty before this filing date? Find Prior Art